These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 22681935

  • 1. PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.
    Däpp S, Müller C, Garayoa EG, Bläuenstein P, Maes V, Brans L, Tourwé DA, Schibli R.
    EJNMMI Res; 2012 Jun 09; 2(1):24. PubMed ID: 22681935
    [Abstract] [Full Text] [Related]

  • 2. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S, García Garayoa E, Maes V, Brans L, Tourwé DA, Müller C, Schibli R.
    Nucl Med Biol; 2011 Oct 09; 38(7):997-1009. PubMed ID: 21982571
    [Abstract] [Full Text] [Related]

  • 3.
    Shan L.
    ; 2004 Oct 09. PubMed ID: 22514805
    [Abstract] [Full Text] [Related]

  • 4. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.
    Schroeder RP, Müller C, Reneman S, Melis ML, Breeman WA, de Blois E, Bangma CH, Krenning EP, van Weerden WM, de Jong M.
    Eur J Nucl Med Mol Imaging; 2010 Jul 09; 37(7):1386-96. PubMed ID: 20182713
    [Abstract] [Full Text] [Related]

  • 5. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.
    de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP, de Jong M.
    Eur J Nucl Med Mol Imaging; 2007 Aug 09; 34(8):1228-38. PubMed ID: 17287960
    [Abstract] [Full Text] [Related]

  • 6. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR.
    Eur J Nucl Med Mol Imaging; 2007 Aug 09; 34(8):1198-208. PubMed ID: 17262215
    [Abstract] [Full Text] [Related]

  • 7. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC.
    Nucl Med Biol; 2009 Aug 09; 36(6):591-603. PubMed ID: 19647165
    [Abstract] [Full Text] [Related]

  • 8. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
    Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M.
    J Nucl Med; 2005 Apr 09; 46(4):691-9. PubMed ID: 15809493
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.
    Rogers BE, Manna DD, Safavy A.
    Cancer Biother Radiopharm; 2004 Feb 09; 19(1):25-34. PubMed ID: 15068608
    [Abstract] [Full Text] [Related]

  • 10. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.
    J Nucl Med; 2004 Oct 09; 45(10):1776-83. PubMed ID: 15471848
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
    Okarvi SM, Al Jammaz I.
    Nucl Med Biol; 2010 Apr 09; 37(3):277-88. PubMed ID: 20346867
    [Abstract] [Full Text] [Related]

  • 12. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
    Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN.
    Bioconjug Chem; 2004 Apr 09; 15(6):1416-23. PubMed ID: 15546210
    [Abstract] [Full Text] [Related]

  • 13. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.
    Fragogeorgi EA, Zikos C, Gourni E, Bouziotis P, Paravatou-Petsotas M, Loudos G, Mitsokapas N, Xanthopoulos S, Mavri-Vavayanni M, Livaniou E, Varvarigou AD, Archimandritis SC.
    Bioconjug Chem; 2009 May 20; 20(5):856-67. PubMed ID: 19344122
    [Abstract] [Full Text] [Related]

  • 14. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, Volkert WA, Hoffman TJ.
    Nucl Med Biol; 2003 Feb 20; 30(2):101-9. PubMed ID: 12623108
    [Abstract] [Full Text] [Related]

  • 15. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M.
    Eur J Nucl Med Mol Imaging; 2011 Jul 20; 38(7):1257-66. PubMed ID: 21431398
    [Abstract] [Full Text] [Related]

  • 16. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.
    Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, Maina T.
    Eur J Nucl Med Mol Imaging; 2003 Feb 20; 30(2):247-58. PubMed ID: 12552343
    [Abstract] [Full Text] [Related]

  • 17. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z, Mitran B, Rosenström U, Velikyan I, Rosestedt M, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Orlova A.
    Nucl Med Biol; 2015 May 20; 42(5):446-454. PubMed ID: 25684649
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy.
    Breeman WA, Hofland LJ, de Jong M, Bernard BF, Srinivasan A, Kwekkeboom DJ, Visser TJ, Krenning EP.
    Int J Cancer; 1999 May 17; 81(4):658-65. PubMed ID: 10225459
    [Abstract] [Full Text] [Related]

  • 19. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
    Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ.
    Bioconjug Chem; 2003 May 17; 14(4):756-63. PubMed ID: 12862428
    [Abstract] [Full Text] [Related]

  • 20. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP.
    J Nucl Med; 2002 Dec 17; 43(12):1650-6. PubMed ID: 12468515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.